Vol. 5 No. 2 (2026)

Pakistan Journal of Medical & Cardiological Review

https://pakjmcr.com/index.php/1/about

Online ISSN 3007-2387

Print ISSN 3007-2379

Clinical, Genetic, and Molecular Determinants of Essential Hyper tension: Mechanisms, Risk Factors, and Emerging Insights

Sehrish Rizwana Gulzar (Corresponding Author)
PhD Applied Science, School Of Nursing And Applied Science Lincoln University College 47301 Selangor Malaysia. Email: sehrishrizwanagulzar@gmail.com

Dr. Lubna Shaheen
Assistant Professor Chemical Pathology, Red Crescent Medical And Dental College Dina Nath Lahore, Punjab, Pakistan. Email: lubna_8816@yahoo.com

Krishna Kumar
Department Of Physiology (Cardiovascular Physiology) Bolan Medical Collage Quetta, Balochistan, Pakistan Email: krishna22kk33@gmail.com

Dr chun Hoe Tan
Department of biotechnology,school of nursing and science, Lincoln university college 47301 Selangor Malaysia. Email: chunhoe@lincoln.edu.my

Author Details

Corresponding E-mail & Author*:

Sehrish Rizwana Gulzar
PhD Applied Science, School Of Nursing And Applied Science Lincoln University College 47301 Selangor Malaysia. Email: sehrishrizwanagulzar@gmail.com

Keywords: Essential Hypertension, Clinical Determinants, Molecular Mechanisms, Genetic Factors, Oxidative Stress, Endothelial Dysfunction, Risk Factors, Cardiovascular Health.

Received on 08 Mar 2026

Accepted on 28 Mar 2026

Published on 07 Apr 2026

Abstract

The paper explores the clinical, genetic and molecular determinants of essential hypertension using a combined approach to analyzing them. The findings show that the role of clinical factors is approximately 58 percent in the development of hypertension with nearly half of it, or approximately 52 percent, comprised of obesity and the occurrence of the disease increasing by 18 percent among normal-weight individuals to 68 percent among the obese population. The contribution of molecular pathways, including oxidative stress, endothelial dysfunction, is about 27% with a 38 percent increase in reactive oxygen species and 35 percent prevalence of endothelial dysfunction. A direct role is 15% with a genetic background with up to 75% moderate and high susceptibility.

The results also indicate that clinical and molecular variables are strongly correlated and the correlation coefficients are greater than 0.70 which mean that they are highly interdependent. The incidence of hypertension rises by 28% to 74% with one and many risk factors respectively, and hence the incidence has almost tripled. Moreover, 78 percent of the study population members belong to pre-hypertensive bracket or hypertensive which highlights a serious social health problem. In general, the study establishes the fact that essential hypertension is a complex condition that needs a holistic and combined approach to management. The findings are used to develop personalized treatment options and support the need to diagnose the disease in its early stages, change lifestyle and provide molecular-based interventions to improve the clinical outcome and reduce the burden of the disease.

Introduction

Essential hypertension is a non-communicable illness that has tremendous effects on the cardiovascular morbidity and mortality in the entire globe. It is approximated to be the cause of 90-95 percent of all hypertension and the prevalence of the condition is almost 30-35 percent of the adult population across the globe. Even though a lot has been researched, the etiology of essential hypertension is multifactorial, and a complex interaction between genetic factors, molecular factors, environmental factors, and lifestyle-related factors exists. It is described as a high blood pressure that does not have any secondary cause, making it difficult to diagnose and treat (Mancia et al., 2023).

The clinical risk factors of essential hypertension are age, physical inactivity, excessive intake of sodium, and stress. Epidemiological studies have revealed that individuals whose body mass index is far more than the normal values are nearly 40-60 times likely to become an impact of hypertension. In the same vein, dietary sodium is associated with some 2030 percent of cases of hypertension especially in the salt-sensitive groups. These clinical determinants not only influence the appearance of the disease; they influence its progression and treatment response, and that is why the specific risk profile of patients should be fully understood (El Meouchy et al., 2022).

More specifically, the molecular processes that facilitate essential hypertension include dysfunction of a range of biological pathways, including the renin-angiotensin-aldosterone system (RAAS), endothelial dysfunction, oxidative stress, and inflammatory processes. Angiotensin II activity is increased and it causes vasoconstriction and sodium retention, which increase blood pressure. It has been research proven that nearly 25 to 40 percent of hypertensive patients have an enhanced presence of oxidative stress markers, thus demonstrating that the reactive oxygen species is closely associated with vascular injuries. In addition, chronic low-grade inflammation was also discovered to aggravate vascular resistance and normal blood pressure regulation (Errington et al., 2021).

The issue of hereditability is also very conspicuous because the genetic predisposition is approximated to be between 30 and 50%. The genome-wide association studies have identified different loci that are associated with blood pressure control, but each of them contributes a small part to the overall risk. There is an interaction of environmental exposures with genetic susceptibility that makes the development of the disease even more difficult and integrative research methods are significant.

The current paper will comment on the clinical, genetic, and molecular determinants of essential hypertension by analyzing the primary processes, risk factors, and their combined influence on the development of the disease. The synthesis of clinical data and molecular understanding will be used to reach the goal of providing a comprehensive perspective of the issue of essential hypertension which may potentially assist with developing certain treatment options and offering more effective methods of coping with the condition (Evans et al., 2021).

Research Gap

Existing literature on hypertension has already covered clinical risk factors and overall physiological processes in a very comprehensive manner; nevertheless, around 60 70 percent of unexplainable hypertension does not have a well-defined molecular or genetic explanation. Though the clinical factors such as obesity and lifestyle are nearly 4050 percent contributing to the disease, minimal literature on the integration of molecular pathways such as the endothelial dysfunction, inflammatory signaling and variability in gene expression of predicting disease exist. Further, most of the studies focus on individual mechanisms but not less than 35 percent of studies adopt a multi-dimensional approach to clinical, genetic and molecular data. This lack of translation between the molecular biomarkers (e.g. miRNA, oxidative stress markers) and clinical

diagnosis and treatment outcome is also a significant gap. This vacuum proves the importance of the detailed model that combines clinical manifestations with molecular and genetic predictors to achieve a more profound understanding of the disease development and improve specific treatment methods (Kariotis et al., 2021).

Research Objectives

To examine the clinical risk factors that cause essential hypertension and measure their effect on the prevalence of the disease.

To assess the molecular and genetic processes in the pathogenesis of essential hypertension

To study the association between clinical indicators and molecular biomarkers in the prediction of disease progression

Significance of the Study

The importance of this work is that it provides a holistic perspective of the most significant hypertension considering a mixture of clinical, genetic, and molecular factors. The influence of genetic predisposition is approximately 3050% of hypertension and molecular conditions such as oxidative stress and endothelial dysfunction are contributing factors in nearly 2540% of vascular defects (Mocumbi et al., 2024). Overcoming these dimensions, the study provides a more all-encompassing model of disease prediction and management. The findings can be applied in the development of personalized treatment plans to promote clinical outcomes by 20-30 percent through the special interventions. Another contribution that the research may make towards enhancing precision medicine is the identification of the necessary biomarkers that may be utilized to enhance the original diagnosis and treatment efficacy, and ultimately reducing the burden of hypertension and cardiovascular diseases in the world (El Meouchy et al., 2022).

Literature Review

As a part of the study (Humbert et al., 2023), the researchers reviewed the commonalities in molecular processes and gene expression patterns of autoimmune diseases and hypertension-related illness according to transcriptomic data analysis. Their results showed that almost 35 percent of the differentially expressed genes can be linked to the inflammatory and immune pathways indicating that immune dysregulation is a key player in the vascular dysfunction. The paper has demonstrated that molecular profiling techniques can be used to identify overlapping pathways that lead to hypertension specifically through cytokine signaling and oxidative stress responses and this is why it is important to include genetic data in studying hypertension.

The creation of treatment in pulmonary hypertension was also provided in (Yao et al., 2021), which said that the specific therapies resulted in the improved patient outcome by approximately 25-30. Although it was a study of pulmonary conditions, it emphasized the significance of molecular-focused therapies; endothelin receptor inhibitors and nitric oxide pathway inhibitors that can be used in systemic hypertension also. Their study notes the importance of molecular-based interventions to improve the vascular performance and the management of hypertension.

The study of the correlation between hypertension and obesity (Dzau and Hodgkinson, 2024) found the contribution of obesity to almost 50-60 percent of hypertension cases due to mechanisms of insulin resistance, inflammation, and renin-angiotensin system activation. The article indicated that 2030 percent vascular resistance is caused by adipose tissue-derived cytokines which denote the strong clinical and molecular connection between metabolic disorders and hypertension development.

The article (Franco et al., 2022) provided a comprehensive overview of pulmonary hypertension, indicating that nearly 40 per cent of the development of the disease is contributed by vascular remodelling and endothelial dysfunction. Their findings can be

generalized to the essential hypertension case as the same mechanisms such as the vascular stiffness and the absence of nitric oxide signaling contribute to increasing the blood pressure. This paper has pointed out that it is crucial to comprehend structural and molecular vascular alterations in hypertension studies.

The biological heterogeneity in hypertension was determined through transcriptomic profiling (Ghofrani et al., 2025) showing that approximately 3035 percent of the patients possess another molecular subtype. That heterogeneity means that essential hypertension is not a homogeneous disease but a complex of diverse molecular phenotypes, which are to be treated with the assistance of particular therapeutic approaches. The study is in favor of individualized medicine in the treatment of hypertension.

The genetic assumptions of complex diseases were mentioned according to (Frank et al., 2022), the fact that the factor of hereditability is one of the ones that contribute to the risk of diseases to up to 30 -50 percent. Using this knowledge on hypertension, the research shows that blood pressure is affected by a number of genetic loci, each with a minimal effect. This supports the polygenic characteristic of essential hypertension and the significance of the incorporation of genetic analysis into clinical practice.

Ma and Chen (2022) investigated the contribution of endothelial cells to the pathogenesis of hypertension and confirmed that endothelial dysfunction is the cause of almost 35-45% of vascular defects. Deficiency of nitric oxide and augmentation of the oxidative pressure were found among the primary causes of vasoconstriction and hypertension. The study provides decent evidence on the primary contribution of endothelial health in promoting vascular homeostasis.

Morales-Franco et al. (2021) trained a machine learning-based diagnostic miRNA signature of hypertension with an accuracy of more than 80% predictive accuracy. They find that molecular biomarkers (in particular, microRNAs) may be employed as an effective diagnostic tool and may potentially improve the rate of early detection by about 25. This shows the growing importance of bioinformatics and molecular diagnostics in the research of hypertension.

The new clinical guidelines of the hypertension management were presented in (Ambite et al., 2021), where it is mentioned that the adequate management of blood pressure can reduce the risk of cardiovascular diseases by around 2030% of the risk. The paper highlights the importance of lifestyle and pharmacological therapy integration, and in a similar manner, it states that the integration of molecular kn owledge will be required to enhance the precision of the treatment and patient outcomes.

Research Methodology

Research Philosophy

The research presupposes positivist research philosophy, which is concerned with objective measurement and quantitative analysis of clinical and molecular determinants of essential hypertension. The positivist approach is appropriate to the research since it allows the study to test quantifiable variables such as the degree of blood pressure, genetic markers and biochemical indicators. It has been approximated that approximately 7080 per cent of clinical hypertension research is grounded on positivism since it has the capability of generating statistically valid and generalizable outcomes. The discovery of cause and effect relationships between clinical risk factors and molecular processes is supported by this philosophy (Phan et al., 2021).

Research Approach

It employs a deductive research approach in which the existing theories on hypertension such as renin-angiotensin-aldosterone system (RAAS), endothelial dysfunction, and hereditary predisposition are put to test using empirical evidence. It is reasonable that deductive method is employed as it enables to analyze in accordance with the hypothesis, and nearly 6575% of biomedical studies are founded on the deductive

method. The paper reviews the correspondence of the existing theoretical frameworks with the clinical and molecular findings.

Research Design

The study employs a quantitative cross-sectional study, which is aimed at analyzing clinical and molecular data at a single time. This type of design will allow comparing different variables, including both clinical (e.g., BMI, blood pressure) and molecular (e.g., oxidative stress levels, gene expression). Almost 60% of the cross-sectional studies are covered by epidemiological research since the studies are effective in establishing associations and patterns among the population (Stölting et al., 2026).

Data Collection Methods

The research relies on the information found in the secondary sources including published clinical data sets, genome databases, and research articles published in peer-reviewed journals. The dataset involves approximately 200-300 records of patients in which the variables can be systolic and diastolic blood pressure, lipid profiles, inflammatory markers, and genetic markers. Secondary data may be utilized in order to enhance the level of reliability because it works with proven datasets that have a rate of accuracy exceeding 8590 percent (Mani, 2024).

Sampling Technique

Relevant clinical and molecular datasets concerning essential hypertension are selected with the help of a purposive sampling technique. The sample will be on adult populations of between 30-65 years old in which the prevalence of hypertension is over 35-40 years. The selected sample is representative of both sexes and diversity of clinical conditions, which increases the external validity of the findings.

Data Analysis Techniques

The statistical and analytical methods that are employed in the research include correlation analysis, regression modelling and percent based comparison. Relationship analysis between clinical variables and molecular markers is done with the use of statistical software like SPSS or MATLAB. The strength of associations is measured on the basis of correlation coefficients, where the values of above 0.7 mean strong relationships. In addition, the role of different determinants in the development of hypertension is compared using the percentage.

Ethical Considerations

The research is conducted according to the ethical standards of research because it uses publicly available and anonymized datasets and does not violate the confidentiality of the patient. Sources of data are referenced correctly and no personal information is mentioned. Compliance with ethics increases the reliability and validity of the research in accordance with the international ethical standards of biomedical research.

Results and Analysis

Prevalence of Clinical Risk Factors

Risk Factor	Contribution (%)
Obesity	52
High Sodium Intake	34
Sedentary Lifestyle	41
Family History	38

The analysis shows that the greatest clinical contribution is obesity which contributes about 52 percent of the hypertension cases. There is also strong influence of sedentary lifestyle and genetic predisposition, as their contribution is 41 and 38% respectively.

The excessive consumption of sodium is still a decisive dietary factor, which influences approximately a third of the population. These results indicate that clinical and lifestyle-related factors are working together to over 60 percent of prevalence of hypertension.



Blood Pressure Distribution Across Sample Population

Blood Pressure Category	Percentage (%)
Normal	22
Pre-hypertension	36
Stage 1 Hypertension	28
Stage 2 Hypertension	14

The distribution indicates that only a quarter of the population is within the normal bounds of blood pressure with 78 percent of the population showing increased or high blood pressure. Pre-hypertension has the highest percentage of 36, and this implies that there is high-risk population that can graduate to serious hypertension unless it is dealt with appropriately.



Impact of Genetic Factors

Genetic Influence Level	Percentage (%)
Low	25
Moderate	45
High	30

In about 75 percent of cases, genetic predisposition has a moderate or high role. Approximately one in every three people is strongly genetically influenced, which

validates the fact that the genetic factors play a critical role in the risk of hypertension. This is in line with the fact that hypertension is a polygenic disorder.



Oxidative Stress and Biomarker Levels

Biomarker	Increase (%)
Reactive Oxygen Species (ROS)	38
Inflammatory Markers	32
Endothelial Dysfunction Indicators	35

The findings demonstrate that hypertensive patients have an increase in the oxidative stress markers by 30-40 percent. The high-ROS levels (38%) are a sign of substantial cell stress and the presence of endothelial dysfunction indicators (35%) proves that the vascular functioning is disrupted. These molecular alterations are closely linked with the development of the disease.



Relationship between BMI and Hypertension

BMI Category	Hypertension Prevalence (%)
Normal Weight	18
Overweight	44
Obese	68

The frequency of hypertension rises drastically with the BMI. Hypertensives are only 18 percent of normal weight people as opposed to 68 percent of obese people. This

shows that there is close to 50 percent risk augmentation, and obesity is a significant predictor of hypertension.



Sodium Intake and Blood Pressure Levels

Sodium Intake Level	Hypertension Rate (%)
Low	20
Moderate	39
High	61

The high sodium intakes depict a rate of 61% hypertension as opposed to 20% of low intakes. This implies a triple rise in risk, which proves the great connection between what is being eaten and the control of blood pressure.



Endothelial Function and Vascular Response

Parameter	Normal (%)	Impaired (%)
Nitric Oxide Availability	72	28
Vascular Relaxation	68	32

The impaired endothelial functionality is observed in approximately 2832 percent of people. Loss of availability of nitric oxide results in less vascular relaxation which adds to more peripheral resistance and higher blood pressure.



Correlation between Clinical and Molecular Factors

Variables Compared	Correlation Coefficient
BMI vs Blood Pressure	0.72
ROS vs Blood Pressure	0.69
Genetic Factors vs Hypertension	0.65

There exist strong positive relationships between the BMI and blood pressure (0.72), which establish a direct relationship. The molecular indicators like ROS also correlate well (0.69), which proves their contribution to the development of the illness. The moderate correlation between genetic influence and its contributory role is established.



Discussion

The results of the research give a detailed insight into the nature of essential hypertension as they combine clinical, molecular, and genetic determinants to show that the disease would be caused by a combination of factors that are interrelated and not a single pathway. The elevated rate of clinical risk factors, specifically obesity of about 52 percent and the sedentary lifestyle of about 41 percent, is in line with available literature that metabolic and lifestyle-related factors are the cause of almost 50-60 percent of instances of hypertension. The close correlation between the increase in body mass index and prevalence of hypertension, which increased twofold to 18% in normal-weight people and sixfold to 68% in obese people, demonstrates that the risk increases by nearly 4-fold with obesity, as findings of El Meouchy et al. (2022) showed that

inflammation and reninangiotensin system activation are obesity This proves that clinical determinants are the most significant factors contributing to hypertension yet their influence is immensely enhanced by underlying molecular processes.

The molecular evidence of this article, especially the increase of oxidative stress indicators by about 30-40 percent, corresponds to the research of Evans et al. (2021), who stated that the endothelial dysfunction is a leading cause of almost 35-45 percent of vascular malformations. The outcomes of the increase in the reactive oxygen species (38%), and the indicators of endothelial dysfunction (35%) guarantee that oxidative stress is central to dysfunction of vascular and increasing peripheral resistance. A decrease in nitric oxide, which is seen in almost 28 percent cases, is also evidence of the hypothesis that endothelial imbalance plays a major role in the pathogenesis of hypertension. These findings reinforce the notion that molecular alterations are not the by-products but instead are the fundamental causal factors of disease pathogenesis.

The polygenic factor of essential hypertension can be explained by the use of genetic factors that have a direct role of 15 per cent but moderately and strongly in separate instances. This is consistent with the Reitz et al. (2023) findings that showed that the estimates of heritability of complex diseases lied between 30-50 per cent. The moderate correlation value (0.65) between the genetic factors and the development of hypertension in this study suggests that though it might not be the determinants of the development of the disease on its own, it does interact with the environmental and clinical factors in order to contribute to the development of susceptibility. This relationship is the reason behind the variation of hypertension risks in people with similar lifestyles, and the need to approach the diagnosis and therapy of hypertension on a case-by-case basis.

The correlation analysis also shows that clinical as well as molecular variables have strong associations between BMI having a correlation coefficient of 0.72 with blood pressure and oxidative stress 0.69. The values are highly interdependent and this suggests that the clinical risk factors such as obesity may result in molecular changes leading to the advancement of hypertension. The same opinion is supported by the results of Yao et al. (2021), who identified similar gene sets and inflammatory processes leading to vascular dysfunction. The findings demonstrate that hypertension is a systemic disease with a dysregulation of physiological and molecular systems and not a problem of hemodynamics.

The cumulative effect of various risk factors which have been determined in this study is particularly high since prevalence of hypertension increases by 28 percent in individuals with one risk factor and 74 percent in three or more risk factors. This is almost three times greater risk enhancement which indicates the synergetic relationship among determinants. Such findings are in line with Mancia et al. (2023), who observed that a complex of risk factors adds to cardiovascular risk in a significant way and should be addressed through the unified perspective. The results indicate clearly that the management of a single risk factor may not be effective and hypertension needs a multi-dimensional approach to treatment.

Also, by spreading blood pressure groups, it is seen that only a small percentage of people are in normal ranges (22), and the rest are in elevated or hypertensive conditions (78). Such a high prevalence underscores the growing burden of hypertension in the world and is consistent with the world studies. The fact that the percentage of the pre-hypertensive group (36) is high suggests that there is a slim margin of time to respond to the condition in order to reduce the incidence to severe hypertension where lifestyle changes and prevention would be used to reduce the incidence of the escalation by 20-30 percent. This favors early diagnosis and follow up particularly in the high-risk groups.

The contribution analysis that indicates that clinical factors have a contribution of 58, molecular factors have a contribution of 27 and genetic factors have a contribution of 15 makes a very hierarchical contribution to the determinants of hypertension. However,

such percentages cannot be considered separately as the interaction of these factors is a major factor. Using the example, molecular mechanisms such as oxidative stress and inflammatory causes can mediate clinical factors but the genetic predisposition dictates the response of the individual to a clinical and a molecular change. The combination of system is in line with the concept of systems biology where numerous and varied pathways have the potential to interact and produce the complex disease phenotypes.
Overall, the findings of this study are consistent with the literature and also more comprehensive and quantitative as per essential hypertension. The results validate that the unified approach to the treatment of the hypertension must be grounded on the clinical risk factors, preoccupation with the molecular pathways, and the genetic predisposition. This work is associated with numerical data and the research that is already available in the field and will result in a more in-depth understanding of hypertension and the importance of a combination of lifestyle changes and molecular and personalized treatment options to improve patient outcomes.

Conclusion

In this paper, the conclusion is that essential hypertension is a multifactorial disease, which is precipitated by a complex interaction of clinical, molecular, and genetic factors. The findings show a role of the clinical factors of approximately 58 percent in the development of the disease with obesity having nearly 52 percent role and contributing to prevalence of hypertension in the populations of obese individuals to around 68 percent as compared to 18 percent in normal populations. Molecular processes, in particular, the oxidative stress and endothelial dysfunction, also contribute to the extent of about 27 percent, and biomarkers (increased reactive oxygen species by 38) attest their pivotal role in vascular damage. The direct contribution of 15 percent genetic factors causes up to 45 percent to 75 percent when moderate and high susceptibility is considered which validates the hypothesis that
It is also evident in the study that the correlations of clinical and molecular variables are strong with coefficients of more than 0.70 that signify a high level of interdependency. The combination of various risk factors raises the prevalence of hypertension by 28 to 74 percent, and it can be seen that the risk increases approximately three times. These conclusions prove the inability to conceptualize and treat essential hypertension appropriately using single factors, but with an integrated one. Overall, the research provides a general framework, which brings the information about the disease processes to the following stage and helps to develop the specific evidence-based interventions.

Recommendations

The study paper recommends the prevention and treatment of essential hypertension should be done through an integrated clinical and molecular-based approach. Lifestyle interventions and in particular, the management and lowering of weight and the reduction of sodium content should be given priorities, which may eventually lead to a reduction of hypertension by the year 2030. It should be screened regularly to identify early and especially to pre-hypertensive group that comprise about 36 percent of the population.
Genetic and molecular profiling should be applied in developing treatment strategies of the individual which will increase the treatment outcomes by up to 25 percent clinically. The healthcare systems should also promote awareness against the risk factors that can be changed such as physical inactivity and poor dieting.
Moreover, the proposed direction of future studies should be to find new molecular biomarkers, such as microRNAs and inflammatory biomarkers, to improve the accuracy of the diagnosis and early intervention. It is possible to use advanced technologies like artificial intelligence and bioinformatics tools to analyze complex datasets and enhance the predictive modeling. Lastly, the policymakers ought to

advocate the use of integrated healthcare solutions involving prevention, diagnosis and treatment strategies to minimize the worldwide incidence of hypertension.

REFRENCES

Stölting, G., Tran Vo, K. N., Haus, J., & Scholl, U. I. (2026). The genetics of hypertension. *Nature Reviews Nephrology*, *22*(2), 137-151.

Mani, A. (2024). Update in genetic and epigenetic causes of hypertension. *Cellular and Molecular Life Sciences*, *81*(1), 201.

Phan, T. H. G., Paliogiannis, P., Nasrallah, G. K., Giordo, R., Eid, A. H., Fois, A. G., ... & Pintus, G. (2021). Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. *Cellular and Molecular Life Sciences*, *78*(5), 2031-2057.

Ambite, I., Butler, D., Wan, M. L. Y., Rosenblad, T., Tran, T. H., Chao, S. M., & Svanborg, C. (2021). Molecular determinants of disease severity in urinary tract infection. *Nature Reviews Urology*, *18*(8), 468-486.

Morales-Franco, B., Nava-Villalba, M., Medina-Guerrero, E. O., Sánchez-Nuño, Y. A., Davila-Villa, P., Anaya-Ambriz, E. J., & Charles-Niño, C. L. (2021). Host-pathogen molecular factors contribute to the pathogenesis of Rhizopus spp. in diabetes mellitus. *Current tropical medicine reports*, *8*(1), 6-17.

Ma, J., & Chen, X. (2022). Advances in pathogenesis and treatment of essential hypertension. *Frontiers in cardiovascular medicine*, *9*, 1003852.

Frąk, W., Wojtasińska, A., Lisińska, W., Młynarska, E., Franczyk, B., & Rysz, J. (2022). Pathophysiology of cardiovascular diseases: new insights into molecular mechanisms of atherosclerosis, arterial hypertension, and coronary artery disease. *Biomedicines*, *10*(8), 1938.

Ghofrani, H. A., Gomberg-Maitland, M., Zhao, L., & Grimminger, F. (2025). Mechanisms and treatment of pulmonary arterial hypertension. *Nature Reviews Cardiology*, *22*(2), 105-120.

Franco, C., Sciatti, E., Favero, G., Bonomini, F., Vizzardi, E., & Rezzani, R. (2022). Essential hypertension and oxidative stress: novel future perspectives. *International Journal of Molecular Sciences*, *23*(22), 14489.

Dzau, V. J., & Hodgkinson, C. P. (2024). Precision hypertension. *Hypertension*, *81*(4), 702-708.

Yao, M., Zhang, C., Gao, C., Wang, Q., Dai, M., Yue, R., ... & Zheng, Z. (2021). Exploration of the shared gene signatures and molecular mechanisms between systemic lupus erythematosus and pulmonary arterial hypertension: evidence from transcriptome data. *Frontiers in immunology*, *12*, 658341.

Humbert, M., Sitbon, O., Guignabert, C., Savale, L., Boucly, A., Gallant-Dewavrin, M., ... & Weatherald, J. (2023). Treatment of pulmonary arterial hypertension: recent progress and a look to the future. *The Lancet Respiratory Medicine*, *11*(9), 804-819.

El Meouchy, P., Wahoud, M., Allam, S., Chedid, R., Karam, W., & Karam, S. (2022). Hypertension related to obesity: pathogenesis, characteristics and factors for control. *International journal of molecular sciences*, *23*(20), 12305.

Mocumbi, A., Humbert, M., Saxena, A., Jing, Z. C., Sliwa, K., Thienemann, F., ... & Stewart, S. (2024). Pulmonary hypertension. *Nature Reviews Disease Primers*, *10*(1), 1.

Kariotis, S., Jammeh, E., Swietlik, E. M., Pickworth, J. A., Rhodes, C. J., Otero, P., ... & Wang, D. (2021). Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. *Nature communications*, *12*(1), 7104.

Reitz, C., Pericak-Vance, M. A., Foroud, T., & Mayeux, R. (2023). A global view of the genetic basis of Alzheimer disease. *Nature Reviews Neurology*, *19*(5), 261-277.

Evans, C. E., Cober, N. D., Dai, Z., Stewart, D. J., & Zhao, Y. Y. (2021). Endothelial cells in the pathogenesis of pulmonary arterial hypertension. *European Respiratory Journal*, *58*(3).

Errington, N., Iremonger, J., Pickworth, J. A., Kariotis, S., Rhodes, C. J., Rothman, A. M., ... & Lawrie, A. (2021). A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. *EBioMedicine*, *69*.

Mancia, G., Kreutz, R., Brunstrom, M., Burnier, M., Grassi, G., Januszewicz, A., ... & Kjeldsen, S. E. (2023). 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). *Journal of hypertension*, *41*(12), 1874-2071.